Clinical Trial Update: A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range) [Phase 3]

View source ↗

Summary

Phase 3 trial of mealtime insulin LY900014 in adults with type 2 diabetes using continuous glucose monitoring has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• LY900014

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2023-03-03